Muhammad Shabbir, MD
Family Medicine · Merced, CANPI 1285879338
Payments from drug & device makers
Across 136 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$317
- Novo Nordisk$251
- GSK$247
- Pfizer$239
- Lilly USA, LLC$131
- Novartis$126
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,50299%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 19 | $317 |
| Novo Nordisk | 13 | $251 |
| GSK | 14 | $247 |
| Pfizer | 15 | $239 |
| Lilly USA, LLC | 8 | $131 |
| Novartis | 7 | $126 |
| AstraZeneca | 6 | $114 |
| Axsome Therapeutics, Inc. | 3 | $101 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $99 |
| Boehringer Ingelheim | 4 | $83 |
| Amgen | 4 | $79 |
| AbbVie | 4 | $78 |
| Hologic Sales And Service, LLC | 4 | $73 |
| Bayer | 3 | $60 |
| Abbott | 2 | $49 |
| Amarin Pharma, Inc. | 3 | $49 |
| Exact Sciences | 2 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Abiomed | 1 | $26 |
| Merck | 2 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Shield Therapeutics Inc | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Gilead | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
How this compares
$2,523 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 372 | $314,073 |
| EliquisApixaban | 167 | $131,208 |
| JanuviaSitagliptin Phosphate | 155 | $130,000 |
| FarxigaDapagliflozin Propanediol | 98 | $113,326 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 160 | $103,763 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 181 | $92,140 |
| LinzessLinaclotide | 92 | $77,435 |
| OzempicSemaglutide | 59 | $69,119 |
| XareltoRivaroxaban | 118 | $55,555 |
| EntrestoSacubitril/Valsartan | 53 | $27,126 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 136 | $24,424 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $24,383 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $20,209 |
| Atorvastatin Calcium | 1,928 | $19,194 |
| TrulicityDulaglutide | 19 | $17,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $83 | $314,073372 claims |
| MerckJanuvia, Dulera | $26 | $134,278166 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $247 | $133,440227 claims |
| PfizerEliquis | $239 | $131,208167 claims |
| AstraZenecaFarxiga | $114 | $113,32698 claims |
| Novo NordiskOzempic, Rybelsus | $251 | $84,12978 claims |
| AbbVieLinzess | $78 | $77,43592 claims |
| Johnson & JohnsonXarelto | $317 | $55,555118 claims |
| NovartisEntresto | $126 | $27,12653 claims |
| Lilly USA, LLCTrulicity | $131 | $17,23719 claims |
| Eisai Inc.Fycompa | $17 | $13,79521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Merced
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.